26 November 2019
Visiongain has published a new pharma report Anti-Idiopathic Pulmonary Fibrosis Drugs Market: Forecast Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs.
The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2018, the anti-fibrotics held the largest market share (51%) followed by the tyrosine kinase inhibitors.
The lead analyst commented that "During the forecast period, the global market is driven by the raising prevalence and incidence of IPF patients, expected launch of novel therapies, special regulatory (Orphan and Fast-track) designations for pipeline molecules, increased understanding of disease pathogenesis, and limited number of current players. However, the global market is curtailed by various challenges during the forecast period with use of off-label drugs, availability of non-pharmacological therapies, and lack of proper diagnosis techniques, as well as absence of highly efficacious & safe drugs."
Leading companies featured in this report include Boehringer Ingelheim, Cipla Limited, Galapagos NV, MediciNova Inc., Merck & Co., Roche, Shionogi & Co. Ltd. and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
06 April 2021
Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.